Novakand Pharma AB (publ) (LARK) - Net Assets

Latest as of December 2025: Skr55.49 Million SEK ≈ $5.97 Million USD

Based on the latest financial reports, Novakand Pharma AB (publ) (LARK) has net assets worth Skr55.49 Million SEK (≈ $5.97 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr56.73 Million ≈ $6.11 Million USD) and total liabilities (Skr1.24 Million ≈ $133.34K USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore LARK asset base for the complete picture of this company's asset base.

Key Net Assets Metrics

Metric	Value
Current Net Assets	Skr55.49 Million
% of Total Assets	97.82%
Annual Growth Rate	49.49%
5-Year Change	-64.94%
10-Year Change	1260.27%
Growth Volatility	230.01

Novakand Pharma AB (publ) - Net Assets Trend (2012–2025)

This chart illustrates how Novakand Pharma AB (publ)'s net assets have evolved over time, based on quarterly financial data. Check LARK goodwill-adjusted equity ratio to evaluate the tangible quality of the company's equity base.

Annual Net Assets for Novakand Pharma AB (publ) (2012–2025)

The table below shows the annual net assets of Novakand Pharma AB (publ) from 2012 to 2025. For live valuation and market cap data, see Novakand Pharma AB (publ) (LARK) market capitalisation.

Year	Net Assets	Change
2025-12-31	Skr55.49 Million ≈ $5.97 Million	-22.47%
2024-12-31	Skr71.58 Million ≈ $7.70 Million	-38.54%
2023-12-31	Skr116.46 Million ≈ $12.53 Million	-23.45%
2022-12-31	Skr152.12 Million ≈ $16.37 Million	-3.89%
2021-12-31	Skr158.28 Million ≈ $17.03 Million	+121.58%
2020-12-31	Skr71.43 Million ≈ $7.69 Million	+251.80%
2019-12-31	Skr20.30 Million ≈ $2.19 Million	-0.74%
2018-12-31	Skr20.46 Million ≈ $2.20 Million	+214.11%
2017-12-31	Skr6.51 Million ≈ $700.81K	+59.63%
2016-12-31	Skr4.08 Million ≈ $439.02K	-60.26%
2015-12-31	Skr10.27 Million ≈ $1.10 Million	+81.20%
2014-12-31	Skr5.67 Million ≈ $609.68K	+846.43%
2013-12-31	Skr598.60K ≈ $64.42K	+100.81%
2012-12-31	Skr298.09K ≈ $32.08K	--

Equity Component Analysis

This analysis shows how different components contribute to Novakand Pharma AB (publ)'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have decreased by 11122609300.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2025)

Component	Amount	Percentage
Common Stock	Skr990.00K	1.78%
Other Comprehensive Income	Skr4.00K	0.01%
Other Components	Skr165.83 Million	298.83%
Total Equity	Skr55.49 Million	100.00%

Novakand Pharma AB (publ) Competitors by Market Cap

The table below lists competitors of Novakand Pharma AB (publ) ranked by their market capitalization.

Company	Market Cap
Dermata Therapeutics Inc NASDAQ:DRMA	$4.91 Million
TENET FINTECH GROUP INC. F:P0T	$4.91 Million
Aptevo Therapeutics Inc NASDAQ:APVO	$4.91 Million
Karma Energy Limited NSE:KARMAENG	$4.91 Million
Pagegroup PLC LSE:PAGE	$4.90 Million
Hapbee Technologies Inc V:HAPB	$4.90 Million
Askari Metals Ltd AU:AS2	$4.90 Million
Jain Irrigation Systems Limited NSE:JISLDVREQS	$4.90 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Novakand Pharma AB (publ)'s equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 71,579,000 to 55,492,000, a change of -16,087,000 (-22.5%).
Net loss of 12,359,000 reduced equity.
Dividend payments of 3,960,000 reduced retained earnings.
Other comprehensive income increased equity by 4,000.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	Skr-12.36 Million	-22.27%
Dividends Paid	Skr3.96 Million	-7.14%
Other Comprehensive Income	Skr4.00K	+0.01%
Other Changes	Skr228.00K	+0.41%
Total Change	Skr-	-22.47%

Book Value vs Market Value Analysis

This analysis compares Novakand Pharma AB (publ)'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 0.82x
The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
The price-to-book ratio has decreased from 158.33x to 0.82x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2012-12-31	Skr0.01	Skr2.30	x
2013-12-31	Skr2.08	Skr2.30	x
2014-12-31	Skr12.81	Skr2.30	x
2015-12-31	Skr19.47	Skr2.30	x
2016-12-31	Skr3.80	Skr2.30	x
2017-12-31	Skr7.96	Skr2.30	x
2018-12-31	Skr14.74	Skr2.30	x
2019-12-31	Skr6.22	Skr2.30	x
2020-12-31	Skr7.74	Skr2.30	x
2021-12-31	Skr9.14	Skr2.30	x
2022-12-31	Skr7.68	Skr2.30	x
2023-12-31	Skr5.88	Skr2.30	x
2024-12-31	Skr3.61	Skr2.30	x
2025-12-31	Skr2.80	Skr2.30	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Novakand Pharma AB (publ) utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): -22.27%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 0.00%
• Asset Turnover: 0.00x
• Equity Multiplier: 1.02x
Recent ROE (-22.27%) is above the historical average (-53.49%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2012	-3.96%	0.00%	0.00x	1.99x	Skr-41.62K
2013	-4.59%	0.00%	0.00x	1.07x	Skr-87.35K
2014	-16.96%	0.00%	0.00x	1.10x	Skr-1.53 Million
2015	-63.02%	0.00%	0.00x	1.07x	Skr-7.50 Million
2016	-212.43%	0.00%	0.00x	1.20x	Skr-9.07 Million
2017	-137.56%	-298.60%	0.37x	1.25x	Skr-9.61 Million
2018	-64.27%	-161379.82%	0.00x	1.72x	Skr-15.19 Million
2019	-96.61%	-119.04%	0.34x	2.37x	Skr-19.69 Million
2020	-43.08%	-284.22%	0.14x	1.11x	Skr-37.92 Million
2021	13.25%	24.95%	0.51x	1.05x	Skr5.14 Million
2022	-4.05%	-23.06%	0.17x	1.04x	Skr-21.37 Million
2023	-30.63%	-643.31%	0.05x	1.04x	Skr-47.31 Million
2024	-62.70%	-13766.26%	0.00x	1.06x	Skr-52.04 Million
2025	-22.27%	0.00%	0.00x	1.02x	Skr-17.91 Million

Industry Comparison

This section compares Novakand Pharma AB (publ)'s net assets metrics with peer companies in the Asset Management industry.

Industry Context

Industry: Asset Management
Average net assets among peers: $1,520,787,848
Average return on equity (ROE) among peers: 0.85%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Novakand Pharma AB (publ) (LARK)	Skr55.49 Million	-3.96%	0.02x	$4.90 Million
Acadian Asset Management Inc (AAMI)	$176.10 Million	77.46%	7.82x	$1.86 Billion
AllianceBernstein Holding L.P. (AB)	$1.53 Billion	10.80%	0.00x	$3.38 Billion
Associated Capital Group Inc (AC)	$964.38 Million	0.92%	0.04x	$78.56 Million
Abrdn Emerging Markets Equity Income Fund Inc (AEF)	$304.00 Million	32.66%	0.17x	$265.69 Million
AgriFORCE Growing Systems Ltd (AGRI)	$8.00 Million	-83.04%	0.47x	$194.14 Million
Alpha Compute Corp (ALP)	$165.43 Million	-10.20%	0.18x	$5.59 Million
Alvarium Tiedemann Holdings Inc. (ALTI)	$17.85 Million	-32.96%	4.15x	$366.82 Million
Affiliated Managers Group Inc (AMG)	$4.97 Billion	4.90%	0.65x	$9.37 Billion
Ameriprise Financial Inc (AMP)	$7.92 Billion	7.96%	12.14x	$40.38 Billion
AMTD IDEA Group (AMTD)	$-854.36 Million	0.00%	0.00x	$40.80 Million

About Novakand Pharma AB (publ)

ST:LARK USA Asset Management

Market Cap

$4.90 Million

Skr45.54 Million SEK

Market Cap Rank

#28666 Global

#5815 in USA

Share Price

Skr2.30

Change (1 day)

+0.00%

52-Week Range

Skr1.84 - Skr2.56

All Time High

Skr2.56